Astellas extends offer to acquire all shares of Ocata TherapeuticsStaff writer ▼ | January 25, 2016
Astellas Pharma has extended the offering period to purchase all issued and outstanding shares of common stock of Ocata Therapeutics.
Acquisition $8.50 per Ocata share
The offer is $8.50 per share, net to the holder in cash until 5:00 pm, U.S. Eastern Time, on February 9, 2016. The tender offer, as previously extended, was scheduled to expire at 5:00 pm, U.S. Eastern Time, on January 21, 2016. The further extension of the tender offer will allow Ocata’s stockholders additional time to tender their shares into the Tender Offer.
All terms and conditions of the tender offer shall remain unchanged during the extended offering period.
“We remain very excited about the combination of Astellas and Ocata and are fully committed to achieving a successful completion of the transaction,” commented Yoshihiko Hatanaka, President and CEO, Astellas. ■